

# C. Brendan Johnson

SHAREHOLDER

St. Louis, MO | 314.622.6144  
[brendanjohnson@polsinelli.com](mailto:brendanjohnson@polsinelli.com)



Brendan Johnson has a broad-based corporate practice with concentrations in venture capital, mergers and acquisitions, corporate finance and securities law, and corporate governance matters. He has represented clients ranging from emerging companies to public companies in matters such as private placements of debt and equity securities, mergers and acquisitions, corporate governance, and strategic commercial arrangements. He also has experience with initial public offerings and other public securities offerings as well as SEC periodic reports and proxy materials. In addition, Brendan has represented numerous private equity-backed companies in connection with their acquisition programs and other strategic transactions.

After law school, Brendan served as clerk to the Honorable Frank J. Magill of the U.S. Court of Appeals for the Eighth Circuit.

## Education

- Georgetown University Law Center (J.D., 1995)
- Princeton University (A.B., *cum laude*, 1991)

## Bar Admissions

- Missouri
- Illinois

## Memberships

- The Repertory Theatre of St. Louis, Board Member
- Shakespeare Festival St. Louis, Board of Directors, 2011-2019
- Arts and Education Council of St. Louis
  - Board of Directors, 2011-2021
  - Board Chair, 2018-2019
- St. Louis Capital Alliance, Managing Committee, 2005-2018
- Donald Danforth Plant Science Center, Leadership Council, 2009-2018

## Capabilities

- Venture Capital & Emerging Growth Companies
- Mergers, Acquisitions & Divestitures
- Corporate & Transactional
- Consumer Products & Luxury Goods
- Agribusiness

## Recognition

- Selected for inclusion in *Best Lawyers in America*® for:
  - Corporate Governance Law, 2025-2026
  - Food and Beverage Law, 2024-2026
  - Mergers and Acquisitions Law, 2023-2026

## Languages

- German

## Matters

---

- Represented NewLeaf Symbiotics, Inc., a pioneer and global leader of pink-pigmented facultative methylootrophs (PPFMs), on its \$45 million Series D financing.
- Reorganization and combination of three medical supply companies
- Sale of an agricultural biological products company to a multinational agricultural and chemical company
- Initial public offerings for companies in the tissue paper and in the commercial aviation industries
- Series of bolt-on acquisitions for a private equity-owned medical device company
- Acquisition of a soybean seed company focused on developing and selling high protein and high oleic oil soybeans
- Sale of the assets of a division of a publicly traded electronics components distributor
- Series C preferred stock and royalty interests financing for a venture capital-backed pharmaceutical discovery company
- Acquisition of a global biological products company based in Australia
- Series of early-stage venture capital investment for a multinational agricultural company
- Shelf registration and take-down offerings for an industrial equipment company
- Engagement letters, fairness opinions and proxy disclosure for a national investment bank